Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A R Abdul Razak

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Oncology (Toronto, Ont.)|March 17, 2020
Immunotherapy in soft-tissue sarcomaO Ayodele, A R Abdul Razak
Investigational New Drugs|December 14, 2017
Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov databaseD Shepshelovich, H Goldvaser, L Wang, et al.
The Southeast Asian Journal of Tropical Medicine and Public Health|March 1, 1997
Cockroaches from urban human dwellings: isolation of bacterial pathogens and controlI Vythilingam, J Jeffery, P Oothuman, et al.
Clinical and Experimental Dermatology|January 16, 2004
Warfarin skin necrosis associated with protein S deficiency and a mutation in the methylenetetrahydrofolate reductase geneJ S Byrne, A R Abdul Razak, S Patchett, et al.
Investigational New Drugs|September 15, 2017
Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publicationsD Shepshelovich, H Goldvaser, L Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2012
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neckA R Abdul Razak, D Soulières, S A Laurie, et al.
Investigational New Drugs|July 25, 2016
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumorsJ E Grilley-Olson, P L Bedard, A Fasolo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trialsY Kanjanapan, D Day, M O Butler, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Oncology (Toronto, Ont.)|March 17, 2020
Immunotherapy in soft-tissue sarcomaO Ayodele, A R Abdul Razak
Investigational New Drugs|December 14, 2017
Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov databaseD Shepshelovich, H Goldvaser, L Wang, et al.
The Southeast Asian Journal of Tropical Medicine and Public Health|March 1, 1997
Cockroaches from urban human dwellings: isolation of bacterial pathogens and controlI Vythilingam, J Jeffery, P Oothuman, et al.
Clinical and Experimental Dermatology|January 16, 2004
Warfarin skin necrosis associated with protein S deficiency and a mutation in the methylenetetrahydrofolate reductase geneJ S Byrne, A R Abdul Razak, S Patchett, et al.
Investigational New Drugs|September 15, 2017
Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publicationsD Shepshelovich, H Goldvaser, L Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2012
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neckA R Abdul Razak, D Soulières, S A Laurie, et al.
Investigational New Drugs|July 25, 2016
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumorsJ E Grilley-Olson, P L Bedard, A Fasolo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trialsY Kanjanapan, D Day, M O Butler, et al.
Pageof 1